Sionna Therapeutics, Common Stock Performance
| SION Stock | 43.70 0.33 0.75% |
On a scale of 0 to 100, Sionna Therapeutics, holds a performance score of 11. The entity has a beta of 1.14, which indicates a somewhat significant risk relative to the market. Sionna Therapeutics, returns are very sensitive to returns on the market. As the market goes up or down, Sionna Therapeutics, is expected to follow. Please check Sionna Therapeutics,'s skewness, and the relationship between the value at risk and day median price , to make a quick decision on whether Sionna Therapeutics,'s existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sionna Therapeutics, Common are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Sionna Therapeutics, displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.74) | Five Day Return 3.87 | Year To Date Return 74.8 | Ten Year Return 74.8 | All Time Return 74.8 |
1 | Disposition of 2047 shares by Booth Bruce of Sionna Therapeutics, at 29.95 subject to Rule 16b-3 | 10/06/2025 |
2 | Disposition of 857 shares by Booth Bruce of Sionna Therapeutics, at 31.03 subject to Rule 16b-3 | 10/13/2025 |
3 | Disposition of 105 shares by Booth Bruce of Sionna Therapeutics, at 29.95 subject to Rule 16b-3 | 10/14/2025 |
4 | Disposition of 200 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 10/16/2025 |
5 | Disposition of 5412 shares by Booth Bruce of Sionna Therapeutics, at 32.33 subject to Rule 16b-3 | 10/20/2025 |
6 | Disposition of 10476 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .58 subject to Rule 16b-3 | 10/28/2025 |
7 | Disposition of 19948 shares by Booth Bruce of Sionna Therapeutics, at 33.87 subject to Rule 16b-3 | 11/07/2025 |
8 | Disposition of 6303 shares by Booth Bruce of Sionna Therapeutics, at 31.12 subject to Rule 16b-3 | 11/13/2025 |
9 | Disposition of 14775 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 11/14/2025 |
10 | Disposition of 2092 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .57 subject to Rule 16b-3 | 11/18/2025 |
11 | Ra Capital Management, L.P. Sells 6,922 Shares of Sionna Therapeutics Stock | 11/20/2025 |
12 | Ra Capital Management, L.P. Sells 47,442 Shares of Sionna Therapeutics Stock | 11/21/2025 |
13 | Sionna Therapeutics to Participate in Upcoming December Investor Conferences | 11/24/2025 |
14 | Disposition of 11890 shares by Thompson Peter A. of Sionna Therapeutics, at 44.6 subject to Rule 16b-3 | 11/25/2025 |
15 | Sionna Therapeutics Earns Underperform Rating from Royal Bank Of Canada | 12/01/2025 |
16 | Disposition of 30049 shares by Cloonan Michael of Sionna Therapeutics, at 6.11 subject to Rule 16b-3 | 12/02/2025 |
17 | Disposition of 10250 shares by Jennifer Fitzpatrick of Sionna Therapeutics, at 40.52 subject to Rule 16b-3 | 12/05/2025 |
18 | Sionna Therapeutics chief legal officer sells 415,330 in stock - Investing.com | 12/09/2025 |
19 | Disposition of 801 shares by Ra Capital Management, L.p. of Sionna Therapeutics, at .89 subject to Rule 16b-3 | 12/12/2025 |
20 | Disposition of 900 shares by Thompson Peter A. of Sionna Therapeutics, at 44.5 subject to Rule 16b-3 | 12/17/2025 |
21 | Disposition of 100 shares by Thompson Peter A. of Sionna Therapeutics, at 44.49 subject to Rule 16b-3 | 12/18/2025 |
22 | Disposition of 875 shares by Thompson Peter A. of Sionna Therapeutics, at 44.49 subject to Rule 16b-3 | 12/19/2025 |
23 | Is Simonds Group Limiteds Stock Price Struggling As A Result Of Its Mixed Financials | 12/24/2025 |
| Begin Period Cash Flow | 39.5 M | |
| Total Cashflows From Investing Activities | -126.9 M |
Sionna Therapeutics, Relative Risk vs. Return Landscape
If you would invest 2,941 in Sionna Therapeutics, Common on September 30, 2025 and sell it today you would earn a total of 1,429 from holding Sionna Therapeutics, Common or generate 48.59% return on investment over 90 days. Sionna Therapeutics, Common is currently generating 0.7515% in daily expected returns and assumes 5.223% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Sionna, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sionna Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sionna Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sionna Therapeutics, Common, and traders can use it to determine the average amount a Sionna Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1439
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SION | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Sionna Therapeutics, is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sionna Therapeutics, by adding it to a well-diversified portfolio.
Sionna Therapeutics, Fundamentals Growth
Sionna Stock prices reflect investors' perceptions of the future prospects and financial health of Sionna Therapeutics,, and Sionna Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sionna Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 44.63 M | ||||
| Price To Book | 6.06 X | ||||
| EBITDA | (69.89 M) | ||||
| Net Income | (61.69 M) | ||||
| Total Debt | 9.75 M | ||||
| Book Value Per Share | 7.23 X | ||||
| Cash Flow From Operations | (52.79 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 1.95 B | ||||
| Total Asset | 185.75 M | ||||
| Retained Earnings | (181.09 M) | ||||
| Working Capital | 140.57 M | ||||
About Sionna Therapeutics, Performance
By examining Sionna Therapeutics,'s fundamental ratios, stakeholders can obtain critical insights into Sionna Therapeutics,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sionna Therapeutics, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | 0.38 | 0.50 |
Things to note about Sionna Therapeutics, performance evaluation
Checking the ongoing alerts about Sionna Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sionna Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sionna Therapeutics, is way too risky over 90 days horizon | |
| Sionna Therapeutics, appears to be risky and price may revert if volatility continues | |
| Sionna Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sionna Therapeutics, generates negative cash flow from operations | |
| Sionna Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is Simonds Group Limiteds Stock Price Struggling As A Result Of Its Mixed Financials |
- Analyzing Sionna Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sionna Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Sionna Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sionna Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sionna Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sionna Therapeutics,'s stock. These opinions can provide insight into Sionna Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sionna Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sionna Therapeutics,. If investors know Sionna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sionna Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sionna Therapeutics, is measured differently than its book value, which is the value of Sionna that is recorded on the company's balance sheet. Investors also form their own opinion of Sionna Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Sionna Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sionna Therapeutics,'s market value can be influenced by many factors that don't directly affect Sionna Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sionna Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.